A r t i c l e s Regulatory T cells (T reg cells) are a unique subset of CD4 + T cells that are essential for controlling autoinflammatory diseases. However, they also prevent beneficial antitumor responses and sterilizing immunity against certain infections. Consequently, the modulation of T reg cell activity and generation of T reg cells ex vivo are important goals of immunotherapy. Naturally occurring, thymus-derived CD4 + T reg cells (nT reg cells) express the lineage-specific transcription factor Foxp3, which is required for their development, homeostasis and function [1] [2] [3] . Despite their limited numbers (5-10% of CD4 + T cells), T reg cells have a pivotal role in immune homeostasis. Indeed, it has been suggested this small population of nT reg cells is able to maintain immune balance through the in vivo conversion of non-T reg cells into suppressive cells, a process called 'infectious tolerance' . This 'contagious' spread of suppression might be a principal mechanism underlying transplantation tolerance 4 and the modulation of autoimmune and inflammatory diseases, such as experimental allergic encephalomyelitis (EAE) 5 and asthma 6 . Although the mechanisms that mediate infectious tolerance remain unclear, the immunomodulatory cytokines transforming growth factor-β (TGF-β) and interleukin 10 (IL-10) have both been linked to this process.
Regulatory T cells (T reg cells) are a unique subset of CD4 + T cells that are essential for controlling autoinflammatory diseases. However, they also prevent beneficial antitumor responses and sterilizing immunity against certain infections. Consequently, the modulation of T reg cell activity and generation of T reg cells ex vivo are important goals of immunotherapy. Naturally occurring, thymus-derived CD4 + T reg cells (nT reg cells) express the lineage-specific transcription factor Foxp3, which is required for their development, homeostasis and function [1] [2] [3] . Despite their limited numbers (5-10% of CD4 + T cells), T reg cells have a pivotal role in immune homeostasis. Indeed, it has been suggested this small population of nT reg cells is able to maintain immune balance through the in vivo conversion of non-T reg cells into suppressive cells, a process called 'infectious tolerance' . This 'contagious' spread of suppression might be a principal mechanism underlying transplantation tolerance 4 and the modulation of autoimmune and inflammatory diseases, such as experimental allergic encephalomyelitis (EAE) 5 and asthma 6 . Although the mechanisms that mediate infectious tolerance remain unclear, the immunomodulatory cytokines transforming growth factor-β (TGF-β) and interleukin 10 (IL-10) have both been linked to this process.
Induced regulatory T cells (iT R cells) can be generated in the periphery or in vitro from conventional CD4 + Foxp3 − T cells (T conv cells) [7] [8] [9] . There is substantial interest in the therapeutic potential of iT R cells because antigen-specific regulatory populations can be generated that are potently inhibitory in vivo 10, 11 . Two types of iT R cells have been described on the basis of the cytokines that induce them:
TGF-β-iT R cells and IL-10-iT R cells. TGF-β-iT R cells are generated after the activation of T cells in the presence of TGF-β with or without retinoic acid and IL-2. Both types of iT R cells are potently suppressive both in vitro and in vivo 10, 12, 13 , but they have distinct molecular signatures. Although TGF-β-iT R cells express Foxp3 and secrete mainly TGF-β, IL-10-iT R cells remain Foxp3 − after conversion and are defined by abundant IL-10 secretion.
T reg cell-based approaches to treating inflammatory conditions such as allergy, autoimmune diseases and graft-versus-host responses have great potential but also have limitations 11 . The therapeutic potential of human T reg cells is limited by their polyclonal specificity, poorly defined markers for enrichment and lower proliferative capacity, which limits ex vivo population expansion. Antigen-specific iT R cells can be generated ex vivo, but their utility is restricted by technical complexities in their generation, their limited potency and/ or ambiguity regarding stability, and their longevity in vivo. Thus, the identification of a well-defined population of T reg cells that can be readily generated ex vivo and are stable and potently inhibitory in vivo is a critical goal for effective cell-based immunotherapy. IL-35 is a T reg cell-specific cytokine that is required for the maximum regulatory activity of mouse T reg cells in vitro and in vivo 14 . In this study, we show that IL-35, like IL-10 and TGF-β, generated human and mouse iT R cells, and we address many issues relating to their in vivo efficacy and stability, generation by nT reg cells and physiological contribution to the regulatory milieu. Figs. 1 and 2) . T conv cells activated with beads coated with antibody to CD3 (anti-CD3) and anti-CD28 in the presence of IL-35 substantially upregulated EBI3 and IL12A mRNA, which encode the two constituents of IL-35 (Ebi3 and p35, respectively; Fig. 1a ), but did not upregulate IL-10 or TGF-β (Supplementary Fig. 3 ). Single-cell analysis by both intracellular cytokine staining (Fig. 1b) and confocal microscopy (Fig. 1c) suggested that treatment with IL-35 induced expression of IL-35 in essentially all IL-35-treated human CD4 + T conv cells, but mock treatment did not. Similarly, CD4 + CD45RA + CD25 − T conv cells from adult peripheral blood expressed EBI3 and IL12A mRNA but not TGFB or IL10 mRNA after activation in the presence of IL-35 but not in its absence (Supplementary Fig. 3i ,j and data not shown).
Regulatory T cells (T reg
We next assessed whether IL-35-treated cells assumed the functional phenotype of iT R cells. T conv cells activated in the presence of IL-35 were hyporesponsive to secondary restimulation, but T conv cells activated in the absence of IL-35 (called 'control-treated cells' here) were not (Fig. 1d) . To determine whether IL-35-pretreated T conv cells had acquired regulatory capacity, we cocultured those cells, as potential suppressors, together with freshly purified responder T conv cells. Although control-treated cells lacked any suppressive capacity, IL-35-treated cells were strongly suppressive (Fig. 1e) . T conv cells treated with human IL-35 also suppressed the proliferation of responder T conv cells across a permeable membrane, in the absence of direct cell contact, but control-treated cells did not (Fig. 1f) , which supported the idea of a role for cytokine-mediated suppression. Moreover, neutralizing anti-IL-35 blocked their suppressive capacity, but anti-IL-10 and anti-TGF-β did not ( Fig. 1g and Supplementary Fig. 3 ). Together these data suggest that IL-35 converts human T conv cells into a homogeneous population of iT R cells that suppress via IL-35.
Suppression by IL-35-treated mouse T conv cells in vitro
Given that human IL-35 mediated the generation of iT R cells, we sought to determine if mouse IL-35 had a similar ability ( Supplementary  Fig. 4) . T conv cells activated in the presence of mouse IL-35 upregulated both Ebi3 and Il12a mRNA but not Il10 or Tgfb mRNA ( Fig. 2a and Supplementary Fig. 5 ). IL-35-treated cells secreted IL-35, which was equivalent to the amount of IL-35 produced by natural T reg cells. Neither control-treated T conv cells nor IL-35-treated Ebi3 −/− T conv cells secreted IL-35 (Fig. 2b) . We next assessed whether IL-35-treated mouse cells, like their human counterparts, assumed an iT R phenotype. As a comparison, we included treatment with other suppressive cytokines (IL-10 and TGF-β), as well as another Ebi3-containing cytokine (IL-27), in the analysis. Consistent with published reports 15 , previously activated T conv cells proliferated well in response to secondary restimulation (Fig. 2c) . T conv cells pretreated with IL-10 and IL-27 also proliferated in response to restimulation (Supplementary Fig. 6 ). However, T conv cells pretreated with either IL-35 or TGF-β were hyporesponsive to restimulation, albeit to a lesser degree than were freshly purified nT reg cells. To determine whether these cytokine-pretreated T conv cells had acquired a regulatory ability, we cultured them, as potential suppressor cells, together with freshly purified responder T conv cells ( Fig. 2d and Supplementary  Fig. 6 ). Whereas control-treated, IL-10-treated and IL-27-treated T conv cells had no effect on the proliferation of responder cells, TGF-β-treated T conv cells suppressed the proliferation of responder T cells 12 . Mouse T conv cells pretreated with IL-35 strongly suppressed the proliferation of responder T cells. Furthermore, IL-35-treated T conv cells suppressed T cell proliferation across a permeable membrane, but control-treated T conv cells did not (Fig. 2e) , which indicated the involvement of soluble suppressive mediators. A concentration of approximately 500-700 pg/ml of IL-35 was required to mediate induction of the expression of Ebi3 and Il12a and of the suppressive phenotype ( Supplementary Fig. 4) .
To determine the mechanism of suppression, we first showed that IL-35-pretreated Il10 −/− T conv cells (which cannot make IL-10) suppressed responder T cells, but Ebi3 −/− T conv cells (which cannot make IL-35) did not (Fig. 2f) . In addition, CD4-dnTGFβRII T conv Fig. 7 ). Analysis with cytokine-neutralizing antibodies showed that IL-35-pretreated T conv cells mediated suppression via IL-35 but not via IL-10 or TGF-β ( Fig. 2g,h ; the anti-Ebi3 used neutralized IL-35 but not IL-27 ( Supplementary Fig. 8 Fig. 9 ). Moreover, Foxp3 −/− T conv cells could be converted into iT R 35 cells that expressed IL-35 and mediated suppression in a manner indistinguishable from that of their wild-type counterparts (Supplementary Fig. 9c ). In addition, iT R Fig. 9d ).
We next compared the global gene expression of iT R 35 cells and iT R con cells by Affymetrix GeneChip microarray. Before these analyses, we verified that the iT R 35 cells used for analysis expressed Ebi3 and Il12a mRNA, secreted IL-35 and suppressed responder T conv cells ( Supplementary  Fig. 10 ). Although we observed differences between nT reg cells and T conv cells, no genes were substantially upregulated or downregulated (over threefold) in iT R 35 cells versus iT R con cells ( Supplementary Fig. 11 ). Nevertheless, the iT R 35 cells generated in five independent experiments expressed Ebi3 and Il12a mRNA, secreted IL-35 and mediated potent in vitro suppression. However, we cannot exclude the possibility that other genes with poor probe sets may be expressed by iT R 35 cells but were not identified in this analysis. We also compared the T reg cell genetic signature with that of iT R 35 cells in a meta-analysis. Although iT R 35 cells and iT R con cells shared expression of some genes with both T reg cells and T conv cells, their expression patterns were nearly identical, which suggested that modest transcriptional changes were responsible for the phenotype observed in iT R 35 cells.
The minimal difference between iT R 35 cells and iT R con cells in their gene-expression profile was further supported by analysis of T cell activation and costimulatory molecule expression and cytokine production. Although the expression of most of the proteins and cytokines examined was indistinguishable in iT R 35 cells versus iT R con cells, we observed less secretion of granulocyte-monocyte colony-stimulatory factor, interferon-γ and IL-4, although the differences were not statistically significant ( Supplementary Fig. 12 ). In addition, surface molecules such as CTLA-4 and CD25, which have been described as mediators of nT reg cell suppression, were similarly upregulated in both iT R 35 cells Mouse: Foxp3 Foxp3 and counted splenic responder (Thy-1.1 + ) and suppressor (Thy-1.2 + ) T cells 7 d later 17 . Thy-1.2 + iT R con cell populations expanded significantly and failed to block the population expansion of Thy 1.1 + responder T conv cells (Fig. 3e,f) . In contrast, Thy- 5, 17 . Consistent with published reports, clinical scores were lower in recipients of nT reg cells, whereas the disease course in mice that received iT R con cells or saline alone was unaffected (Fig. 3g) . Notably, mice treated with iT R 35 cells were completely protected from EAE, whereas mice that received Ebi3 −/− iT R 35 cells were indistinguishable from control mice that received saline, which suggested that IL-35 production by iT R 35 cells in vivo is required for this protection.
T reg cells can prevent antitumor CD8 + T cell responses against the poorly immunogenic B16 melanoma 22, 23 . We adoptively transferred wild-type naive CD4 + CD25 − T cells and CD8 + T cells into Rag1 −/− mice, alone or in combination with nT reg or iT R 35 cells, followed by intradermal injection of B16 melanoma cells, and monitored tumor size daily 17 . Tumors were smaller in recipients of CD4 + and CD8 + T cells that lacked T reg cells than in untreated Rag1 −/− mice (Fig. 3h) . In contrast, transfer of either nT reg cells or iT R 35 cells with CD4 + and CD8 + T cells completely blocked the antitumor response, which resulted in more aggressive tumor growth similar to that of untreated Rag1 −/− mice. Surgical excision of the primary tumor and subsequent secondary tumor challenge at a distal site demonstrated that concomitant tumor immunity was also prevented by both nT reg cells and iT R 35 cells (Supplementary Fig. 13) .
We initiated inflammatory bowel disease (IBD) by adoptive transfer of naive CD4 + CD45RB hi CD25 − T cells into Rag1 −/− recipient mice and monitored disease by assessing weight loss and histopathology of the colon 24 . After mice developed clinical symptoms of IBD (~4 weeks after T cell transfer), they received iT R con cells or iT R 35 cells and were monitored daily 17 . Mice that received iT R 35 cells demonstrated recovery from disease, indicated by weight gain (Fig. 3i) and less histopathology ( Fig. 3j and Supplementary Fig. 13 ), but mice that received iT R con cells did not. We showed that iT R 35 cells were also able to cure IBD induced by CD4-dnTGFβRII T conv cells to further demonstrate that TGF-β is not required for the in vivo suppressive ability of iT R 35 (Supplementary Fig. 14) .
Finally, we assessed the importance of IL-35 production by iT R 35 cells in vivo with a unique Ebi3-specific antibody that neutralized IL-35 but not IL-27 (Supplementary Fig. 8 ). Administration of this antibody blocked the suppressive ability of iT R 35 cells in an in vivo model of homeostatic expansion, but administration of an isotypematched control antibody did not (Supplementary Fig. 13g ), consistent with our observations obtained with Ebi3 −/− or Il12a −/− iT R 35 cells in the three in vivo models (Fig. 3) . Together these data demonstrate that iT R 35 cells have a potent suppressive ability in a wide variety of in vivo models and that this activity is dependent on IL-35 production in vivo.
Stability of iT R 35 cells in vivo
It has been suggested that iT R cells generated ex vivo are unstable in vivo. Although our five in vivo transfer experiments suggested that iT R 35 cells have some degree of stability, we used two approaches to assess this directly. First, we generated CD45.2 + iT R 35 or TGF-β-iT R cells in vitro and adoptively transferred them into CD45.1 + C57BL/6 mice to monitor cell recovery and function over time. We recovered both iT R 35 cells and TGF-β-iT R cells from the spleen after transfer and found that both retained expression of their signature genes (Ebi3 and Il12a (iT R 35) or Foxp3 and Tgfb (TGF-β-iT R ); Supplementary Fig. 15 ). As observed in vitro, inoculation for 3 weeks with iT R 35 cells in vivo failed to induce Foxp3 expression, which suggested that this critical nT reg cell transcription factor is not required for the maintenance and function of iT R 35 cells. Although we recovered 33% of the initial iT R 35 cell inoculum from the spleen 3 weeks after transfer, we recovered only 12% of TGF-β-iT R cells (Fig. 4a) . In addition, purified iT R 35 cells still retained considerable suppressive ability, whereas the function of TGF-β-iT R cells was approximately 50% lower (Fig. 4b) . Although this suggested that iT R 35 cells might be more stable in vivo, it did not exclude the possibility that iT R 35 cells and TGF-β-iT R cells might home to different anatomical locations in the mouse, which could affect their recovery from the spleen. Second, we transferred nT reg cells, iT R 35 cells or TGF-β-iT R cells into 2-to 3-day-old Foxp3 −/− mice and determined how long they could prevent the onset of a moribund state (clinical score ≥4). By 5 weeks after transfer, all recipients of TGF-β-iT R cells were moribund, compared with 40% or 33% of recipients of nT reg cells or iT R 35 cells, respectively (Fig. 4c) . Furthermore, the survival of the remaining recipients of nT reg cells or iT R 35 cells was longer, with 100% morbidity not being reached until 6.5 weeks or 8 weeks, respectively. Although additional experiments are needed to fully evaluate the long-term stability of iT R 35 cells in homeostatic and inflammatory environments, these data suggest that they are functionally stable in vivo and are apparently at least as stable as nT reg cells.
T reg cell-mediated suppression generates iT R 35 cells
It has been suggested that T reg cells can amplify their suppressive ability by converting nonregulatory populations into suppressive A r t i c l e s cells, consistent with the idea of infectious tolerance, and that this process might be cytokine mediated [25] [26] [27] . It is known that nT reg cells are a natural source of IL-35, which increases five-to tenfold after contact with target T conv cells 14, 28 . Thus, we sought to determine whether nT reg cell-derived IL-35 could mediate conversion to iT R 35 cells. We first purified T conv cells that had been cultured with and suppressed by nT reg cells for 3 d (called 'suppressed T conv cells' here) and found that the expression of both Ebi3 and Il12a mRNA was significantly upregulated after coculture to an amount similar to that of nT reg cells (Fig. 5a,b) . Furthermore, suppressed T conv cells generated by culture together with wild-type cells secreted IL-35, but those generated by culture with Ebi3 −/− nT reg cells did not (Fig. 5c) Fig. 16 ), which suggested that TGF-β does not mediate this conversion. These data raise the possibility that iT R 35 cells are generated from the suppressed T conv population. We next assessed whether suppressed T conv cells gained the phenotypic characteristics of a regulatory population. Suppressed T conv cells were profoundly unresponsive to stimulation with anti-CD3 and were potently suppressive in vitro (Fig. 5d,e) . T reg cells can secrete IL-10, TGF-β and IL-35, which might influence their ability to convert T conv cells into suppressed T conv cells. Likewise, the same cytokines could be secreted by suppressed T conv cells and contribute in an autocrine way to their conversion and/or suppressive activity. To address these issues we first cocultured T conv cells and nT reg cells that were wild-type or lacked the ability to produce IL-35 (Ebi3 −/− or Il12a −/− ) or IL-10 (Il10 −/− ), or were unable to respond to TGF-β (CD4-dnTGFβRII). Although the generation of suppressed T conv cells that were hyporesponsive and had a regulatory ability did not require TGF-β-mediated signaling, the absence of both IL-35 and IL-10 from the nT reg cell-T conv cell coculture blocked their development and/or function (Fig. 5d,e) . Further analysis of nT reg cell-T conv cell cocultures in which only one population was mutant showed that both IL-10 and IL-35 derived from nT reg cells was required for the generation of the regulatory suppressed T conv population. IL-35 derived from suppressed T conv cell was also required for conversion, as suggested by analysis of signature genes by quantitative PCR (Supplementary Fig. 15d) .
We included neutralizing antibodies during the conversion process or in the secondary suppression assay to further assess the roles of IL-35, IL-10 and TGF-β (Fig. 5f) . Anti-TGF-β had no effect at either stage, and IL-10 neutralization partially blocked conversion but not the regulatory capacity of suppressed T conv cells, which suggested that IL-10 is required for optimal conversion of suppressed T conv cells into a regulatory population. In contrast, neutralization Fig. 3g ). *P < 0.05, **P < 0.005 and ***P < 0.001 (a-g; unpaired t-test). Data represent at least two independent experiments with eight to twelve mice per group (mean and s.e.m.).
of IL-35 prevented both the conversion and regulatory function of suppressed T conv cells. Collectively, these data suggest that some or all of the suppressed T conv cells were iT R 35 cells. The precise contribution of IL-10 to T reg cell-mediated conversion to iT R 35 cells remains to be fully elucidated, because IL-10 alone did not induce the expression of Ebi3 or Il12a mRNA (Supplementary Fig. 5 ). However, the addition of a low dose of IL-10 seemed to augment the IL-35-mediated conversion, which might help offset the delayed production of IL-35 by nT reg cells (Supplementary Fig. 16c ). Together these data suggest that IL-35, either from a natural source (nT reg cells) or supplemented exogenously, mediates iT R 35 conversion. Next we assessed the regulatory capacity of nT reg cell-suppressed T conv cells (nT reg cell-induced iT R 35 cells) in vivo. First we found that they were able to significantly suppress the homeostatic population expansion of cotransferred naive T conv cells in Rag1 −/− mice in a manner similar to that of nT reg cells and iT R 35 cells (Fig. 5g) . However, suppressed T conv cells generated from Ebi3 −/− T conv cells cultured with wild-type nT reg cells failed to suppress the population expansion of cotransferred T conv cells. Next we found that in the EAE model, peak clinical disease scores were decreased by suppressed T conv cells to a degree similar to that obtained with nT reg cells (Fig. 5h) . However, suppressed T conv cells did not ameliorate EAE as effectively as iT R 35 cells did, which suggested that only a proportion of this suppressed T conv cell population was iT R 35 cells or that conversion in vitro was suboptimal because of the time required for the potentiation of IL-35 production by nT reg cells 14, 28 . Nevertheless, these data support the idea that iT R 35 cells are generated from T conv cells to some degree by nT reg cells during suppression. In contrast, there was no evidence of the generation of IL-10-iT R cells or TGF-β-iT R cells in this setting.
Induction of iT R 35 cells in vivo by nT reg cells
We reasoned that the generation of iT R 35 cells in vivo would occur predominantly in inflammatory or disease environments in which optimally stimulated nT reg cells might be secreting large amounts of IL-35. Infection with Trichuris muris, an intestinal nematode, promotes T reg cell responses in the large intestine 29 . Thus, using the CD4 + Foxp3 − Ebi3 + IL-12a + iT R 35 cell signature, we assessed whether iT R 35 cells were detectable after T. muris infection. We infected Foxp3 gfp mice with T. muris and purified Foxp3 + and Foxp3 − T cells from spleens, small intestines and large intestines 14 d after infection. The expression of both Ebi3 and Il12a was much higher in Foxp3 + T reg cells in both the small and large intestines than it was in splenic T reg cells (Fig. 6a,b) , consistent with published observations that nT reg cells result in tenfold higher IL-35 expression in the presence of T conv cells 14 . Although we observed essentially no expression of Ebi3 or Il12a in splenic Foxp3 − CD4 + T cells, their expression was substantial in similar isolates from the small intestines and especially the large intestines (the main site of infection). Indeed, the expression of Ebi3 and Il12a was statistically indistinguishable in Foxp3 + T reg cells and Foxp3 − CD4 + T cells from the large intestines. IL-35 expression by naive, activated or memory CD4 + T cells has not been reported 14 , and Foxp3 − CD4 + T cells from the intestines or mesentaeric lymph nodes of uninfected mice did not express Ebi3 or Il12a (data not shown), which raised the possibility that iT R 35 cells were being generated by T reg cells in this inflammatory microenvironment.
The inflammation induced by solid tumors attracts T reg cells [30] [31] [32] [33] [34] [35] . Using B16 melanoma and MC38 colorectal adenocarcinoma as model systems 22, 36, 37 , we inoculated Foxp3 gfp mice with tumor cells, resected solid tumors 15-17 d after transfer (B16) or 12 d after transfer (MC38) and purified Foxp3 + and Foxp3 − T cells from spleens and tumors. Tumor-infiltrating Foxp3 + T reg cells had much higher expression of both Ebi3 and Il12a (Fig. 6c-f) . Tumor-infiltrating Foxp3 − T cells also substantially upregulated their expression of Ebi3 and Il12a. We made similar observations in the two distinct tumor types. We further analyzed IL-35 secretion and its physiological relevance in the B16 melanoma system. Although we observed moderate secretion of Fig. 6g) Fig. 7) . Analysis of congenically marked tumor-infiltrating CD4 + T cells confirmed high expression of Ebi3 and Il12a similar to that of T reg cells (Supplementary Fig. 17 ). Fig. 18 ).
DISCUSSION
We have shown here that iT R 35 cells represent unique members of the T reg cell family that were generated by IL-35 and mediated their suppression exclusively via IL-35. They did not express Foxp3, did not require the other key suppressive cytokines (IL-10 or TGF-β) for conversion and were distinct from the known induced regulatory populations of TGF-β-iT R cells and IL-10-iT R cells. We found that iT R 35 cells were generated by a single, short-term stimulation of the T cell antigen receptor in the presence of IL-35 (mouse,3 d; humans, 6 d), unlike the other iT R populations described before, TGFβ iT R and IL-10-iT R cells, which require longer conversion protocols, multiple cell types and/or additional molecules for optimal generation 13, 38, 39 . Infectious tolerance, whereby T reg cells confer a suppressive phenotype on T conv cells, has been described in both mouse and human systems 25, 27 . It has been suggested that TGF-β might have a critical role in mediating infectious tolerance 40 Whether a similar system operates in humans remains to be determined. Studies suggest that human T reg cells do not make 42) ; however, our unpublished data challenge those observations and emphasize the importance of further elucidation. Nevertheless, human iT R 35 clls were generated and suppressed the proliferation of primary human T cells in an IL-35-dependent manner. Furthermore, mouse iT R 35 cells were potently suppressive in five distinct in vivo models. The potential therapeutic application of ex vivo-generated IL-10-iT R cells and TGF-β-iT R cells is complicated by complexities in their generation, their short halflife and reversal of their suppressive capacity over time or by IL-2 (refs. 12,43,44) . Although additional experiments are needed to fully assess the clinical potential of iT R 35 cells, our data suggest that they represent a highly potent and stable iT R population that might have considerable therapeutic utility.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Accession codes. GEO: microarray data, GSE24210 (series) and GSM595497-GSM595512 (specific array files).
Note: Supplementary information is available on the Nature Immunology website.
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